WebTasuku Kitada is Co-founder, Director, President, and Head of R&D at Strand Therapeutics . 4 Companies in Career N/A Related Markets 3 Colleagues N/A Related Investments Aliases N/A industry Biotech R&D including Therapeutics, Molecular Diagnostics (no marketing prod. yet) tags Molecular Cloning, Molecular Biology Topics of Influence N/A … Web10 Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA, USA. [email protected]. 11 Candriam Investors Group, Brussels, Belgium. …
Tasuku Kitada AIChE
WebFeb 9, 2024 · Programming gene and engineered-cell therapies with synthetic biology Authors Tasuku Kitada 1 , Breanna DiAndreth 1 , Brian Teague 1 , Ron Weiss 2 … WebApr 9, 2024 · 术平台中,抗体,Mersana将应用其专业知识和专有的Dolasynthen平台Dolasynthen的技术平台能够在抗体上的特定位置偶联产生功来开发新的... ruby software engineer
Strand Therapeutics’ mRNA Logic Circuits Enhance Gene …
WebJan 15, 2011 · Tasuku Kitada 1 , Thomas Schleker , Adam S Sperling , Wei Xie , Susan M Gasser , Michael Grunstein Affiliation 1 Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. PMID: 21212735 PMCID: PMC3033431 DOI: 10.4161/cc.10.2.14536 Abstract WebSep 15, 2024 · Kitada and Becraft were the first to create synthetic gene circuits using synthetic mRNA, showing that post-transcriptional circuits could be “wired” to create a variety of networks that enabled cell type-specific expression and small molecule-based control of gene expression from synthetic mRNA. WebTasuku Kitada Strand Therapeutics Cambridge, MA 02142 [email protected] Michael Lingzhi Li MIT Operations Research Center 77 Massachusetts Avenue, E40-103 Cambridge, MA 02139 [email protected] Andrew W. Lo MIT Sloan School of Management 100 Main Street, E62-618 Cambridge, MA 02142 and NBER [email protected] Kevin Shi … ruby soho heel turn